Health
Roche Shares Drop on Concern About Obesity Pill Side Effects
- Most patients developed side effects like nausea or vomiting
- Roche’s pill may be easier to make than Novo and Lilly shots
This article is for subscribers only.
Roche Holding AG’s shares slid the most in more than a month after its closely-watched experimental obesity pill was tied to side effects, raising questions about the drugmaker’s competitiveness in the hottest new pharmaceutical market.
Roche dropped as much as 5% in early trading in Zurich on Thursday after releasing results of a small study that showed high rates of nausea and vomiting, as well as other side effects. The company presented the findings late Wednesday to a packed audience at the European Association for the Study of Diabetes meeting in Madrid.